Hope for Autoimmune Sufferers: Calibr-Skaggs’ Innovative CAR-T Therapy Clears FDA Hurdle

San Diego, CA – [Current Date] – A significant advancement in the fight against chronic autoimmune diseases has been announced today, with the Calibr-Skaggs Institute for Innovative Medicines revealing that the U.S. Food and Drug Management (FDA) has greenlit their investigational new drug (IND) submission for a novel switchable chimeric antigen receptor T cell (sCAR-T) therapy.This groundbreaking treatment, known as CLBR001 + SWI019, is poised to enter a Phase 1 clinical trial, with patient recruitment set to commence shortly (NCT06913608).

The trial will initially focus on evaluating the safety and efficacy of CLBR001 + SWI019 in patients battling debilitating autoimmune conditions including myositis, systemic sclerosis, lupus, and rheumatoid arthritis. The program holds the potential for future expansion to encompass a wider range of autoimmune indications.

This innovative sCAR-T therapy addresses a critical challenge in current CAR-T approaches for autoimmune diseases: the necessity for lymphodepletion. This preliminary chemotherapy procedure, while crucial for conventional CAR-T efficacy, often entails increased risks of infection and severe side effects, posing a significant burden for both patients and rheumatologists. Calibr-Skaggs’ CLBR001 + SWI019 is engineered to circumvent this requirement, aiming to reduce side effects and broaden access to this potentially life-changing treatment.

Autoimmune diseases,affecting an estimated 15 million individuals in the U.S. and up to 12% of the global population, are frequently enough chronic and considerably impact quality of life. CAR-T cell therapy has shown promise in offering a curative path for certain autoimmune conditions by effectively resetting the immune system, diminishing the reliance on lifelong immunosuppressive medications.

“Patients with chronic autoimmune diseases need curative options that do not require life-long immunosuppressive therapy to manage their condition,” stated Travis Young, vice president of biologics at Calibr-Skaggs. “our CLBR001 + SWI019 cell therapy has the potential to transform the treatment paradigm for patients by eliminating chemotherapy-associated risks.”

Echoing this sentiment, Calibr-Skaggs’ Chief Medical Officer, Chan Beals, remarked, “successfully establishing safety and efficacy of CLBR001 + SWI019 for conditions like lupus and rheumatoid arthritis could pave the way for broader therapeutic use in other autoimmune diseases, offering new hope to many more patients in the future.”

The CLBR001 + SWI019 switchable CAR-T cell therapy distinguishes itself through a two-component system: the sCAR-T cell (CLBR001) and a protein-based biologic “switch” (SWI019). This combination targets CD19-positive B cells, offering a precise and controlled approach. The therapy has already demonstrated encouraging outcomes in treating B cell malignancies, with the ability to mitigate adverse effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Preclinical studies have further highlighted it’s unique capacity to function effectively without the need for lymphodepletion. Early-stage trials have indicated that CLBR001 cells exhibit robust expansion and persistence in patients compared to approved CAR-T cell products.

With patient enrollment for the pivotal clinical trial anticipated to begin soon,this progress marks a significant stride towards a new era of treatment for autoimmune diseases.

How does the “switch” mechanism in switchable CAR-T cell therapy address the risks of cytokine release syndrome (CRS) and neurotoxicity associated with traditional CAR-T therapy?

Switchable CAR-T Therapy Gets FDA Approval for Autoimmune Disease Trials

Understanding the Breakthrough in Immunotherapy

The Food and Drug Administration (FDA) has recently granted approval for clinical trials investigating switchable CAR-T cell therapy as a potential treatment for several autoimmune diseases. This marks a notable leap forward in immunotherapy, offering a possibly safer and more controllable approach compared to traditional CAR-T cell therapies primarily used in cancer treatment.This new generation of CAR-T cell therapy addresses a critical limitation of earlier iterations: the risk of prolonged and potentially hazardous immune activation.

What is CAR-T Cell Therapy? A Quick Recap

Chimeric Antigen Receptor (CAR) T-cell therapy involves genetically engineering a patient’s own T cells to express a receptor (the CAR) that specifically recognizes a target antigen, frequently enough found on cancer cells. These modified T cells are then infused back into the patient to seek out and destroy cells expressing that antigen. While incredibly effective in certain blood cancers like leukemia and lymphoma, the “one-and-done” nature of traditional CAR-T therapy poses challenges when applied to autoimmune conditions. In autoimmunity, the target isn’t a foreign invader but the body’s own tissues. Uncontrolled T-cell activation can lead to severe side effects, including cytokine release syndrome (CRS) and neurotoxicity.

The Innovation: Switchable CARs

Switchable CAR-T cells incorporate a molecular “switch” that allows clinicians to control the activity of the engineered T cells.This switch can be activated or deactivated using a small molecule drug, offering unprecedented control over the immune response.

Here’s how it works:

Conditional Activation: The CAR receptor is designed to only function when bound to a specific activating molecule.

Rapid Deactivation: Removing the activating molecule quickly shuts down the CAR-T cell activity, mitigating potential toxicity.

Tunable Response: The level of activation can be adjusted by varying the dose of the activating molecule, allowing for a personalized and finely tuned immune response.

Small Molecule-Activated CARs: Utilizing drugs that bind to the CAR receptor, triggering its activation.

Light-Activated CARs (Optogenetics): Employing light to control CAR-T cell activity – currently more experimental.

Split CARs: Dividing the CAR into two components, requiring both to be present for activation.

Autoimmune Diseases Targeted in Initial Trials

The FDA approvals currently cover trials focusing on several debilitating autoimmune diseases, including:

Systemic Lupus Erythematosus (SLE): A chronic inflammatory disease affecting multiple organs. CAR-T therapy for lupus aims to target autoantibodies and autoreactive B cells.

Rheumatoid Arthritis (RA): An autoimmune disease causing inflammation of the joints. Trials are exploring targeting specific immune cells involved in joint destruction.

Type 1 Diabetes (T1D): An autoimmune disease where the immune system attacks insulin-producing cells in the pancreas. CAR-T cell therapy for type 1 diabetes focuses on preserving beta cell function.

Multiple Sclerosis (MS): A chronic, often disabling disease that affects the central nervous system. Research is investigating targeting autoreactive T cells that attack myelin.

Myasthenia Gravis: A neuromuscular disorder causing muscle weakness.

Enhanced Safety: Reduced risk of severe CRS and neurotoxicity.

Improved Efficacy: Precise control over immune response can lead to better disease management.

Personalized Medicine: Treatment can be tailored to individual patient needs.

Potential for Remission: Long-term disease control and potential for remission are possible.

Off-Target Effects: The CAR-T cells might still target healthy cells, although the switchable nature minimizes this risk.

Immune Suppression: Over-suppression of the immune system could increase susceptibility to infections.

Activating molecule Toxicity: The drug used to activate the CAR-T cells may have its own side effects.

Long-Term Effects: The long-term consequences of switchable CAR-T therapy are still unknown.

**Optimizing Switch Design